The Brand That Refused Its Own Category

What building Curaleaf in 2013 taught me about betting against the obvious

The most important decisions in the Curaleaf brand are the ones you can’t see.

There was no leaf on the logo. No green cross. No cartoon, no pun, no wink. No slang anywhere in the system — not because a rule forbade it, but because the entire brand was built as if the rule existed. In 2013, when Connecticut opened applications for its medical cannabis program, every expected code of the category was available to us. We refused nearly all of them.

That refusal had to be argued for. This is the story of the argument.

The room

Connecticut had announced it would license only four producers from a field of sixteen applicants, under what the state intended to be the most stringent medical cannabis program in the country. I was brought in to brand one of the sixteen — a room of seven investors, among them former Goldman Sachs and Credit Suisse executives, alongside the founders: a lawyer and a nurse.

The room had an idea of what a cannabis brand should be. Botanical. Natural. A soft, herbal warmth — the aesthetic of a wellness shop, somewhere between apothecary and headshop. It was a reasonable instinct. It was also, I believed, exactly wrong.

The argument I made was simple: we didn’t need to sell weed to people who already bought weed. That market existed and required no persuasion. The opportunity — and the entire point of a medical program — was everyone else. The skeptics. The patients who qualified but hesitated.

So I asked the room a question. Could this material sit credibly in a doctor’s office? And could a physician look at a 60-year-old grandmother suffering through chemotherapy and advise her that the answer to her nausea was two hits of Sour Diesel in the morning?

The first question pointed to a direction. The second demanded a study.

The study

With art director Steven Sarkozy, I surveyed the naming conventions of the pharmaceutical products our qualifying patients — people with cancer, Parkinson’s, epilepsy, MS — already took. Emend. Zoloft. Ambien. Invega. Then we set those against the existing cannabis lexicon: Gold Mist. Healthy High. Fuzzy Wuzzy. Jurassic Haze. Sour Diesel.

We put the two lists side by side and let the room look at them.

No one needed the conclusion explained. One vocabulary belonged in a hospital. The other belonged somewhere a hesitant patient — or her doctor, or a state regulator — would never follow. The gap between those columns was the entire strategy: a regulated medical category was being born, and it had inherited a language that disqualified it from its own future.

There was one more piece of found language working in our favor. The illicit history belonged to the word marijuana — Connecticut’s own program was named the Medical Marijuana Program. But cannabis was still relatively unclaimed, not yet fully baked into the public lexicon. The category’s clean vocabulary was sitting there, available. We built on it.

The name

The name I brought in was Curaleaf — cura, Latin for care, joined to the plant, with relief and cure folded into its sound.

It was initially torn down. The founder who had assembled the investors and driven the licensing effort rejected it as off, as cliché. So rather than defend it, I opened the naming exercise to the room. The investors generated alternatives. The alternatives were duds — earnest, forgettable, or worse, botanical. After the duds had made the case for me, I circled back to Curaleaf.

It landed immediately. Consensus, no hesitation. The name hadn’t changed; the room had. It now had a frame for what the name was doing — familiar enough to trust, distinct enough to own, and aligned with a position everyone had come to understand. Sometimes the argument for the right answer is letting the wrong answers audition first.

The audience nobody briefs you on

Here is the part of the strategy I’ve never seen written about in category work: the most important audience wasn’t the patient or the investor. It was the scorer.

Steven and I read the state’s licensing regulations a dozen times. We knew what was taboo before we designed a single element. And we understood something specific about who would be evaluating the applications: the board included people who also regulated pharmaceuticals in Connecticut. To them, botanical whimsy would read as foreign — a headshop asking for a medical license. But pharmaceutical codes would read as native. Familiar. Fluent in the reviewers’ own professional language.

So the system was built to be legible to that room first. A custom typeface — approachable, but at home beside pharma marks. Light and dark green, silkscreened pill bottles, labels carrying batch numbers and cannabinoid profiles like any regulated medication. Product naming split into Daytime and Nighttime — Primora and Lunora, built on the root ora — structured the way medicine is structured, not the way strains are named. Patient decision guides. Physician materials. Testimonial campaigns built on real patients and real doctors, in a warm, plain register. Even the distribution plan spoke the language: unmarked white vehicles, plain boxes, the only branding a strip of packing tape.

The refusals went all the way down.

What held

The bet was that legitimacy, not subculture, was the actual competitive advantage. In January 2014, Curaleaf was awarded its license — with the highest marketing score of the sixteen applicants. The identity later became the master brand under which the company grew into the largest cannabis operators in the United States by market share, retail and geographic footprint.

Was everything right? No. In retrospect, the earliest packaging was stripped down to the point of blandness — safe when safety was the mandate, with room it never used to grow more expressive as the category matured. That’s the honest cost of designing for the scorer first: you sometimes sand off more character than the moment strictly required.

But the two objectives I’d given the client were: pass the regulations, and build a brand worth acquiring. Both held.

The larger lesson isn’t about cannabis. It’s that in an emerging category, the expected codes are usually inherited from the category’s past — and the past is often the thing the category is trying to escape. The obvious direction had a decade of baggage attached. The contrarian direction had none, because it borrowed its legitimacy from an adjacent world that had spent a century earning it.

The full brand system — the naming architecture, the typeface, the campaign work — is documented in the Curaleaf case study on my site.

Michael Mikulec is a brand strategist, creative director, and writer whose work focuses on identity systems for emerging and complex categories. He named and launched Curaleaf, and his work has included brand and design systems for NBC, ESPN, Fenway Park’s centennial, and other sports, media, and cultural organizations. He served as Chair of Graphic Design at SCAD and writes American Alchemy, an essay series on memory, design, and American identity. More at michaelmikulec.com.